Satellos Bioscience (MSLE) Stock Price, News & Analysis

Company Overview

Satellos Bioscience Inc. is a biotechnology company focused on developing regenerative medicines for conditions involving skeletal muscle damage, degeneration, or impaired repair. The company’s research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and regenerating muscle tissue.

Satellos’ lead product candidate is SAT-3247, an orally administered small-molecule therapy designed to enhance the activation and function of muscle stem cells. The company is evaluating this approach for potential use in diseases characterized by progressive muscle weakness, including Duchenne muscular dystrophy and other muscle disorders.

Satellos Bioscience is headquartered in Vancouver, British Columbia, and is developing its therapies for international pharmaceutical and biotechnology markets. The company’s programs remain investigational, and their safety and effectiveness have not been established for marketing use.

Key Stats

• Today's Range: $9.31 to $9.75
• 50-Day Range: $8.35 to $10.19
• 52-Week Range: $5.30 to $13.39
• Volume: 19,815 shs
• Average Volume: 26,693 shs
• Market Capitalization: $197.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.75
• Consensus Rating: Moderate Buy

Satellos Bioscience Stock Analysis - MarketRank™

Satellos Bioscience scored higher than 37% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Satellos Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Satellos Bioscience has a consensus price target of $19.75, representing about 111.9% upside from its current price of $9.32.

Amount of Analyst Coverage

Satellos Bioscience has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Satellos Bioscience are expected to decrease in the coming year, from ($2.08) to ($2.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Satellos Bioscience is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Satellos Bioscience has a P/B Ratio of 5.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.68% of the float of Satellos Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Satellos Bioscience has a short interest ratio ("days to cover") of 4.28.

Change versus previous month

Short interest in Satellos Bioscience has recently decreased by 2.84%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Satellos Bioscience does not currently pay a dividend.

Dividend Growth

Satellos Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Satellos Bioscience this week, compared to 3 articles on an average week.

MarketBeat Follows

3 people have added Satellos Bioscience to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Satellos Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

37.90% of the stock of Satellos Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Satellos Bioscience has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MSLE
• CIK: 1421642
• Web: satellos.com
• Phone: (647) 660-1780
• Fax: 604-602-9699
• Employees: 18
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Satellos Bioscience: $19.75
• High Price Target: $23.00
• Low Price Target: $18.00
• Potential Upside/Downside: +111.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.87 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.97%
• Return on Assets: -65.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.22
• Quick Ratio: 11.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.80 per share
• Price / Book: 5.18

Miscellaneous

• Outstanding Shares: 21,220,000
• Free Float: 13,175,000
• Market Cap: $197.77 million
• Optionable: N/A
• Beta: 1.53